Director of Screening
Helen Harrison is Director of Screening at Amphista Therapeutics. From the company’s new lab facility at Granta Park, she leads development, validation and execution of a range of plate-based assays, profiling the company’s unique degrader molecules. Her team utilises a wide range of technologies to enable high-throughput screening and support the company’s rapidly expanding pipeline.
Helen has over 18 years experience in biochemical and cell-based assay development and screening, with particular experience in building teams and robust screening cascades in dynamic biotech environments. She moved to Amphista in 2021 from Bicycle Therapeutics, which she joined as a Research Scientist in the infancy of the company, taking an early and key role in establishing the internal assay and screening capabilities. As the company grew, Helen progressed into a Director role, managing the assay team and becoming heavily involved in external partnerships and collaborations.
Helen obtained BSc and Masters degrees in Medical Sciences from the University of Leeds and the Open University respectively. Earlier in her career, she has also held roles in assay development and screening at Paradigm Therapeutics/Takeda Cambridge and GSK.